Introduction
large genomes ranging in size from 125-235 kbp and these large genomes encode more than 50 gene products that are essential for viral replication (Coen & Shaffer, 2003) . Although any viral protein essential for viral replication is a potential target, nearly all currently available drugs for herpesviruses are primarly inhibitors of viral DNA polymerase ( Figure 1 ). These drugs are divided into three chemical groups: nucleoside analogues, nucleoside phosphonate (nucleotide) analogues and pyrophosphate analogues (Visalle & van Zeijl, 2003) . The first group includes acyclovir (ACV), ganciclovir (GCV), penciclovir (PCV), brivudin (BVDU); the second group includes cidofovir (CDV); and the third group includes foscarnet (PFA).
Nucleoside and nucleotide analogues are substrates for the viral DNA polymerase. The nucleoside analogues should be converted to triphosphate active form by phosphorylation in the infected cells. The first monophosphorylation of analogues such as ACV, GCV, PCV and BVDU is selectively performed by viral enzymes. These enzymes include thymidine kinase (TK) for HSV-1, HSV-2 and VZV and UL97 protein kinase for HCMV (Elion, 1983; Littler et al. 1992) . Subsequently, the di-and the triphosphorylation of all nucleoside analogues, except for BVDU, are catalysed by cellular enzymes. The di-phosphorylation of BVDU depends on viral TK. The triphosphorylated active forms compete with the binding of normal triphosphates (dNTPs) as a substrsate for viral DNA polymerase. Incorporation of nucleoside analogues into nacent DNA blocks DNA elongation. Because the nucleoside analogues, ACV, GCV and PCV have poor bioavailability, the bioavailable prodrugs of these analogues, valacyclovir, valganciclovir and famciclovir have been developed respectively. The oral administration of these prodrugs results in the higher plasma levels and is very useful and convenient for the treatments in HSV, VZV and HCMV infections. Therefore, ACV, GCV, PCV and their prodrugs are the first choice for these viral infections. However, the long-term treatment of immunocompromised patients with these drugs results in the development of resistant viruses which cause sometime serious lifethreatening infections in immunocompromised hosts. The majority of clinically isolated resistant strains have the mutation(s) in TK gene in HSV and VZV or UL97 gene in HCMV, while some has the mutations in both viral phosphotransferase gene and viral DNA polymerase gene.
BVDU, a pyridine-containing nucleoside analogue, is a potent inhibitor of alphaherpesviruses and is especially effective against VZV (De Clercq & Walker, 1984) . BVDU is orally available and extremely successful in the treatment of herpes zoster (Wutzler et al., 1995) . However, BVDU does not have worldwide approval for treatment of VZV infections; currently, it is approved only in Germany.
When virus resistant to the first line nucleoside analogues develops, either PFA or CDV are used as a second choice for treatment. PFA, a pyrophosphate analogue, directly inhibits the viral DNA polymerase (Crumpacker, 1992) . CDV, a nucleoside phosphonate, becomes an active form by two cellular phosphorylation enzymes and inhibits viral DNA polymerase (Neyts & De Clercq, 1994; Cihlar & Chen, 1996) . Both of these drugs show poor bioavailability. PFA is more widely distributed and is used for drugresistant virus infections. Fomivirsen is the first licensed antisense oligonucleotide to inhibit HCMV immediate-early 2 (IE2) gene transcription (Perry & Balfour, 1999) . This drug is used only for the treatment of HCMV retinitis via direct intraocular inoculation (Leeds et al., 1997) .
Treatment of immunocompromised patients with current antiherpesvirus drugs results in the development of drug-resistant virus. Because all of the current antivirals target the same active sites on viral kinase and viral DNA polymerase molecules, mutant virus resistant to one drug often show cross-resistance to other drugs. In addition, although ACV is not particularly toxic, all anti-HCMV drugs exhibit toxic side effects. These drawbacks of antivirals for herpesvirus infections can be overcome by new compounds that prevent viral replication by inhibiting either an entirely different enzyme function or one which is already targeted by virtue of a new compound binding site (Visalle & Zeijl, 2003) .
Inhibitors of viral DNA synthesis

Non-nucleoside herpesvirus DNA polymerase inhibitors
Large libraries of compounds were screened (by automatic high-throughput in vitro assay) for inhibition of HCMV DNA polymerase identified naphthalene carboxamide, PNU-26370, as the lead compound. From PNU-26370, 4-hyroxyquinoline-3-carboxamides were chemically synthesized as a novel class of non-nucleoside, broad-spectrum inhibitors of herpesvirus DNA polymerases. Additional chemical modification of this class yielded the more potent 4-oxo-dihydroquinolines (4-oxo-DHQs) ( Figure 2 ), as represented by PNU-182171 and PNU-183792 Knechtel et al., 2002; Wathen, 2002) . PNU-182171 and PNU-183792 inhibited not only the HCMV DNA polymerase, but also the HSV-1, HSV-2 and VZV DNA polymerases, and PNU-183792 was also shown to inhibit the HHV-8 DNA polymerase. In contrast, PNU-183792 did not inhibit HHV-6 DNA polymerase (Thomsen et al., 2003) . These compounds did not inhibit the polymerase activity of cellular DNA polymerases α or δ; nor do they inhibit the mitochondrial DNA polymerase γ. In antiviral cell culture assays, PNU-182171 and PNU-183792 inhibited replication of HSV-1, HSV-2, VZV and HCMV; PNU-183792 was also found to inhibit HHV-8 replication. However, in agreement with the in vitro polymerase assay, PNU-183792 did not inhibit the replication of HHV-6.
In order to investigate the mode of action of the 4-oxo-DHQs, HSV-resistant viruses were selected in the presence of 20 µM PNU-182171 (Thomsen et al., 2003) . The sequencing of the mutants' DNA polymerase genes revealed that they carried a single point mutation, resulting in a V823A amino acid (or the equivalent amino acid in HSV-2) change, located within conserved domain III of the herpesvirus DNA polymerase gene. HCMV-resistant virus was also found to have amino acid changes at V823A and V824L within conserved domain III. V823 is conserved in the DNA polymerase of six of the eight human herpesviruses (HSV-1, HSV-2, VZV, HCMV, EBV and HHV-8); polymerase of the other two, HHV-6 and HHV-7, contained an alanine at codon 823. In HHV-6 polymerase, the change of amino acid from alanine to valine at codon 823 altered polymerase activity, resulting in inhibition of the enzyme by 4-oxo-DHQs. In addition, the 4-oxo-DHQresistant HSV-1, HSV-2 and HCMV mutants did not have altered susceptibility to current nucleoside analogues; in fact, some mutants were hypersensitive to several of the drugs (Thomsen et al., 2003) . 4-oxo-DHQs' broad spectrum of antiherpesvirus activity makes these compounds potential agents for prophylaxis of herpesvirus diseases in immunocompromised patients (Wathen, 2002) .
Helicase/primase complex inhibitors
The helicase/primase complex is known to be an essential component of the DNA replication of herpesviruses (Crumpacker & Shaffer, 2002) . The HSV helicase/primase complex is composed of three viral proteins (the products of UL5, UL8 and UL52 genes) and contains intrinsic DNA helicase, RNA polymerase (primase) and ssDNAstimulated ATPase activities (Crute & Lehman, 1991; Zhu & Weller, 1992) . The helicase/primase complex unwinds double-stranded viral DNA and generates primers for lagging strand synthesis by the viral DNA polymerase ( Figure 3) (Crute et al., 2002; Kleymann et al., 2002; Crumpacker & Schaffer, 2002) . The thiazole urea derivative, BAY-57-1293, inhibited ssDNA-stimulated ATPase activity and the thiazolylphenyl derivative, BILS 179BS, inhibited the activities of viral helicase, primase and ssDNA-stimulated ATPase. The enhancement of affinity between enzyme and DNA by BILS 179 BS resulted in preventing the propagation of HSV helicase/primase catalytic cycles (Crute et al., 2002) . Both of these compounds inhibited the in vitro replication of HSV-1 and HSV-2 more effectively than ACV, and were also effective against ACV-resistant HSV and PAA-resistant HSV-1 (Kleymannn et al., 2002) . In contrast, these compounds showed almost no activity against VZV or HCMV replication. Ten drug-resistant HSV mutants were selected in the presence of 0.5-2.0 µM BAY 57-1293. The frequency of the appearance of mutants (0.5-4.5×10 -5 ) is at least one order of magunitude lower compared with ACV. The mutations in isolated mutants in vitro resistant to these compounds map to UL5 and UL52 genes, indicating that both compounds target helicase/primase complex. The mutations in the UL5 gene of HSV-1 were mainly found between codon 349-359 (the α-helix stretch HEFGNLMKVLE), which is adjacent to the conserved motif IV of the six protein domains required for helicase activity .
These two compounds exhibit low toxicity and a high bioavailability (>60%) in animal models. Both BILS 179 BS and BAY 57-1293 were active orally and showed impressive effects on the healing of HSV-1 and HSV-2 in cutaneously infected mice and HSV-2 in vaginally infected guinea pigs Crute et al., 2002; Betz et al., 2002) . Topical treatment of zosteriform HSV-1 infection with BAY 57-1293 was also effective. In these animal model experiments, both derivatives were superior to ACV and valaciclovir: they reduced time to healing, prevented rebound of disease after cessation of treatment and reduced frequency and severity of recurrent disease. Therefore, the clinical application of these derivatives will be expected to significantly improve the treatment of HSV disease in humans, including those resistant to current medications.
Another compound with a different chemical composition, T-0902611, is a specific inhibitor for HCMV. T-0902611 covalently modifies the HCMV primase component of the helicase/primase complex [Chen et al., 41st Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAC), 2001 , Abstr. F-1672 Powers et al., 41st ICAAC, 2001 , Abstr. F-1673 . T-0902611 is reported to have 30-fold better activity than GCV in vitro. Phase I studies show that the drug was well-tolerated with no observable toxicity to bone marrow. However, a precise evaluation of this drug has not yet been published.
Inhibitors of DNA encapsidation
In the replication of herpesviruses, viral DNA polymerase produces large, complex head-to-tail concatemers (Zhang et al., 1994; Severini et al., 1996) which must be cleaved into genome-length pieces before insertion into preformed capsids (Figure 4 ). Seven HSV-1 genes have been found to be involved in concatemer cleavage and packaging (Visalli & Zeijl, 2003) . They are UL6, UL15, UL17, UL25, UL28, UL32 and UL33. The homologues of these genes exist in other herpesviruses; in the case of HCMV, for example, they are UL104, UL89, UL93, UL77, UL56, UL52 and UL51, respectively (Chee et al., 1985) . HCMV UL56 and UL89 products are thought to make up the heterodimeric HCMV terminase complex (Scheffczik et al., 2002; Giesen et al., 2000) . The HCMV UL89/UL56 complex has DNA binding activity and specifically recognizes packaging (pac) sequences located near the ends of herpesvirus genomes (Bonger et al., 1998) . In addition, the UL89/UL56 complex possesses nucleolytic activity and ATPase activity (Figure 4 ). Another key protein in encapsidation is HSV-1 UL6 and the equivalent gene products of other herpesviruses ( Figure  4) . The UL6 gene product forms the portal protein through which the DNA can enter the procapsid (Newcomb & Brown, 1994 , 2002 Newcomb et al., 2001a,b) .
Inhibitors of terminase complex
The first compounds targeting HCMV terminase complex were benzimidazole ribonucleoside derivatives, BDCRB and TCRB. These compounds were potent and selective inhibitors of HCMV replication but not murine CMV (Townsend et al., 1995) . Mutants resistant to TCRB and BDCRB had the mutations in HCMV UL56 and UL89 genes Krosky et al., 1998) . It was also revealed that BDCRB inhibits the nuclease activity of UL89 gene product and ATPase activity of UL56 gene product (Scheffczik et al., 2002; Scholz et al., 2003) . Although these compounds showed good oral bioavailability, half-life in the plasma is relatively short (Good et al., 1994) . Therefore, many additional analogues were synthesized, including 1263W94 (maribavir) and 275175X (175X). Although 175X is an analogue of BDCRB in which D-ribose is in the pyranosyl form, maribavir is an Lribofuranosyl nucleoside (Williams et al., 2003) . 175X exhibits greater bioavailability and reduced serum proteinbinding. This compound acts as an inhibitor of terminase complex, similar to BDCRB (Figure 4 ). Maribavir has a completely different function, as described later.
Another class of compound, phenylenediaminesulphonamide , was reported to inhibit the cleavage of concatemeric HCMV DNA in cell culture . The resistant mutations have been mapped in HCMV UL89 and UL56 genes (Buerger et al., Figure 5 . The inhibitors of portal protein 2001). However, BAY 38-4766 has a different molecular mode of action from benzimidazole ribonucleosides; BAY 38-4766 resistant mutants did not show cross-resistance to benzimindazole ribonucleoside derivatives (Evers et al., 2002) . In addition, BAY 38-4766 inhibited not only the replication of HCMV, but also animal CMVs such as murine CMV, rat CMV and rhesus CMV Reefshlaeger et al., 2001; Weber et al., 2001) . Phase I clinical trails revealed that BAY 38-4766 was well-tolerated and achieved plasma concentrations in excess of HCMV IC 50 with a single dose of 500 mg or greater (Reefshlaeger et al., 2001; Weber et al., 2001) .
Inhibitors of portal protein
Two thiourea derivatives, WAY-150138 and Comp 1, were reported to inhibit HSV-1 and VSV, respectively ( Figure 5 ). WAY-150138 specifically inhibited HSV-1, but not other herpesviruses; Comp 1 specifically inhibited VZV, but not other human herpesvirus or simian varicella virus (SVV) (van Zeijl et al., 2000; . The mutations resistant to WAY-150138 and Comp 1 have been mapped to HSV UL6 gene and VZV ORF54 gene (the UL6 equivalent of HSV), respectively (van Zeijl et al., 2000; . Although there was minimal difference between the two derivatives, reciprocal activity was not observed.
Other inhibitors
5-Chloro-1,3-dihydroxyacridone, a cellular topoisomerase II inhibitor, was reported to inhibit the replication of HSV ( Figure 6 ). This compound inhibited DNA maturation and also reduced capsid production (Akanitapichat & Bastow, 2002) . Because drug resistant mutants have not yet been isolated, the precise target of this compound remains undetermined at present. Recently, bicyclic furopyrimidine nucleosides bearing an aryl side chain (BCNAs) have been proved to be highly potent and selective inhibitors for VZV (McGuigan et al., 2000) . Some of these compounds were 10000-fold more effective than ACV.
Inhibitor of HCMV UL97 protein kinase
As mentioned above, maribavir is an unnatural L-ribofuranosyl nucleoside (Figure 7) . Maribavir showed significant antiviral potency in vitro against both laboratory strains and clinical isolates of HCMV, including those resistant to GCV, PFA and BDCRB (McSharry et al., 2001; Williams et al., 2003) . The mutation in maribavir-resistant mutants has been mapped to the HCMV UL97 protein kinase gene (Biron et al., 2002; Baek et al., 2002) . Indeed, it has been shown that maribavir targets UL97 protein kinase and inhibits the activity of wild-type UL97 protein kinase (Biron et al., 2002) . However, it is still controversial which stage of the replication cycle is inhibited by marbavir because the precise function of UL97 protein kinase in the replication cycle has not yet been demonstrated. One group reported that maribavir inhibited viral DNA replication without the inhibition of viral DNA polymerase (Biron et al., 2002) , while another reported that maribavir blocks HCMV replication at the stage of nuclear egress, when DNA-containing capsids are transferred from nucleus to cytoplasm (Krosky et al., 2003) . A third group reported that UL97 null mutants mainly block at the stage of encapsidation of viral DNA without effects on viral DNA cleavage (Wolf et al., 2001) .
Maribavir was safely administrated as single oral dose of 50 to 1600 mg to healthy and HIV-infected adults and pharmacokinetics (PK) were dose proportional over the dose range tested. Phase I trail revealed that maribavir was rapidly absorbed after oral dosing and demonstrated linear PK with steady-state plasma maribavir profiles. Marvabir showed in vivo anti-HCMV activity in semen in HIVinfected adults, with mean reduction in semen HCMV titres of 2.9-3.7 log 10 (Lalezari et al., 2002) . Maribavir was generally well-tolerated and most frequently reported side effect was taste disturbance. Although the precise stage at which maribavir is effective is still controversial, clinical application of maribavir will be expected in the near future.
Several protein kinase inhibitors (PKIs) were analysed and indolocarbazoles, K252a, K252c and Gö6976, proved to be highly effective inhibitors of GCV-sensitive and resistant HCMVs (Zimmerman et al., 2000) . These compounds were fully effective when added up to 24 h postinfection. These indolocarbazoles strongly inhibited both autophosphorylation of UL97 protein and UL97 protein kinase-dependent phosphorylation of GCV.
Cellular proteins as antiviral targets
To ensure specificity and avoid toxicity, the antivirals currently available target viral proteins. The drawbacks of such drugs is that they only exhibit activity against a few closely related viruses and contribute to the development of resistant viruses. In contrast, the antiviral drugs targeting cellular proteins essential for viral replication would not be constrained by these limitations (Coen & Schaffer, 2003) . However, the inhibitors of cellular proteins may show significant side effects. Although antivirals targeting cellular protein are not yet available, some inhibitors of cellular proteins inhibit viral replication. A pharmacological cyclin-dependent kinase (cdk) inhibitor, roscovitine, inhibited HSV-1, HSV-2 and HIV-1, but not vaccinia virus or lymphocytic choriomeningitis virus (LCMV); inhibited replication of strains of HSV-1 and HIV-1 resistant to conventional antiviral drugs; and binds to the same subset of proteins in mock-and HSV-infected cells (Schang et al., 2002) . These lines of evidence indicate that roscovitine inhibits virus replication by targeting cellular proteins. However, roscovitine is rather less effective than indolocarbazoles, protein kinase inhibitors (PKIs) (Zimmerman et al., 2000) .
Another cellular target is cyclooxygenase-2 (COX-2) which is one of the cellular enzymes induced after HCMV infection (Zhu et al., 2002) . Prostaglandin E2, a product of COX-2 activity, is also produced more than 50-fold after HCMV infection. Non-cytotoxic COX-2 inhibitors inhibited the induction of COX-2, prostaglandin E2 and the replication of HCMV by 100-fold. COX-2 inhibitors block accumulation of HCMV immediate early 2 (IE2) but not IE1, mRNA or viral DNA replication.
Conclusions
As the number of immunocompromised hosts, such as cancer, organ transplant and AIDS patients, has increased, the need for controlling herpesvirus infections has become routine everywhere. Since idoxuridine was first introduced to treat herpes keratitis, effective antivirals have been developed and used for the treatment of herpesvirus infections. Because nearly all of these antivirals target viral DNA polymerase, long-term therapy leads to the appearance of drugresistant viruses. In the past several years, however, new antivirals which target different viral proteins have been developed to overcome cross-resistance. Although these new compounds are still at the pre-clinical phase, some compounds are expected to reach the clinical stage in the near future.
The current range of antivirals and all the new compounds target the viral molecules essential for viral replication; how to eliminate latent virus still remains to be elucidated. In order to address this issue, it is essential that the viral and cellular molecular mechanisms involved in latency are elucidated.
